ALK and non-small cell lung carcinoma: Among these kinase domains, eight residues (I1171, F1174, L1196, L1198, G1202, D1203, L1256, G1269) are responsible for lorlatinib resistance in ALK fusion-positive NSCLC in clinical setting and/or experimental models7,9,13,22.